Life Tech and GSK to Co-Develop qPCR-Based Companion Dx for Investigative Cancer Immunotherapy | GenomeWeb

By Ben Butkus

This story has been updated from a version posted Oct. 25 to include comments from a GlaxoSmithKline spokesperson.

Life Technologies said yesterday that it has inked an agreement with GlaxoSmithKline Biologicals to develop a qPCR-based molecular diagnostic assay to help select patients who may benefit from a GSK candidate cancer immunotherapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.